Precision BioSciences Launches Stock and Pre-Funded Warrant Offering on Heels of Hepatitis B Data
DTIL has more than doubled off its 52-week low of $3.53.
Summary
Precision BioSciences is offering common stock and pre-funded warrants under its January 7, 2026 shelf, with size and pricing left blank in this free writing prospectus. Proceeds fund PBGENE-HBV and PBGENE-DMD development and working capital.
Updates
· BusinessWire — Precision priced the offering at $7.75 per share for 10,235,077 shares plus pre-funded warrants for 5,893,964 shares, raising about $125M gross, expected to close November 6, 2026.
Key Events · Financing and Capital Events · DTIL
-
Stock and Pre-Funded Warrant Offering Launched
Precision is offering common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase up to a stated number of shares, under its January 7, 2026 S-3 shelf. The share count and price are left blank in this free writing prospectus.
-
Pre-Funded Warrant Terms Set
Each pre-funded warrant costs the offering price per share minus $0.000005, the exercise price. Warrants never expire, allow cashless exercise, and carry a 4.99% (or 9.99% at the holder's option) ownership blocker adjustable up to 19.99%.
-
Proceeds Earmarked for Two Gene Editing Programs
Net proceeds, amount undisclosed, will fund continued research and development of PBGENE-HBV and PBGENE-DMD plus working capital and general corporate purposes.
-
Offering Timed to Hepatitis B Data
The offering follows same-day disclosure of Phase 1 ELIMINATE-B data: undetectable pgRNA in 100% of evaluable patients at the 0.4 mg/kg go-forward dose, with Phase 2 dosing expected to begin in the first quarter of 2027.
Analysis · DTIL · Life Sciences
Precision is raising capital through a stock and pre-funded warrant offering under its existing January 7, 2026 shelf, timed to same-day PBGENE-HBV Phase 1 data showing undetectable pgRNA in 100% of evaluable patients at the 0.4 mg/kg go-forward dose. The filing leaves the size, price per share, and net proceeds blank, so the dilution cannot be quantified yet. Proceeds are earmarked for PBGENE-HBV and PBGENE-DMD development plus working capital, extending funding for two clinical programs but at the cost of new shares issued into a stock trading at $8.50. The pre-funded warrants carry a $0.000005 exercise price, no expiration, cashless exercise, and a 4.99%/9.99% ownership blocker adjustable up to 19.99%, so they function as deferred equity rather than priced options.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DTIL was trading at $8.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.8M. The 52-week trading range was $3.53 to $9.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.